Analyst Price Targets — MRAI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 28, 2024 7:43 am | Allen Klee | Maxim Group | $6.00 | $2.08 | TheFly | Marpai upgraded to Buy from Hold at Maxim |
Latest News for MRAI
Marketing Agreement Establishes Powerful National Distribution Channel and Expands Marpai's Revenue Growth Opportunity TAMPA, Fla., March 9, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management (PBM) services, today announced the execution of a transformational marketing agreement…
New Client Momentum Highlights Rapid Adoption of Marpai's Disruptive, Scalable Healthcare Platform Positioned to Drive Exponential Revenue Growth and Long-Term Shareholder Value TAMPA, Fla., Feb. 23, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management (PBM) services, today…
TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MRAI.
U.S. House Trading
No House trades found for MRAI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.